Within the realm of healthcare stocks lies a treasure trove of underappreciated gems waiting to be unearthed. While industry giants often hog the spotlight, these unsung heroes provide a unique opportunity for discerning investors to ride the wave of innovation and burgeoning trends.
Despite operating in niche segments, these stocks boast the potential for substantial returns, making them tantalizing growth prospects. As the thirst for growth opportunities within the healthcare sector intensifies, these hidden champions stand poised to outshine the competition in the market landscape.
Stay ahead of the curve as we unveil the top underappreciated healthcare stocks to add to your portfolio this April!
Novo Nordisk (NVO): Resilience in the Face of Adversity
Source: joreks / Shutterstock.com
Novo Nordisk (NYSE:NVO) boldly stands as a Danish multinational pharmaceutical powerhouse, reigning supreme in the diabetes care domain. With a market share that towers over others in insulin products, Novo Nordisk continues to push the boundaries of innovation with novel delivery methods and formulations. Venturing beyond diabetes, the company is venturing into new territories such as obesity and weight management.
The GLP-1 therapies platform by Novo Nordisk is on track to deliver yet another stellar year in 2024. Addressing type 2 diabetes and obesity, these therapies have been the company’s cornerstone in recent times, with demand scaling new heights.
In the fiscal year of 2023, revenues soared a staggering 31% year over year to reach $232.26 billion. Sales in obesity care witnessed an eye-watering surge of 154%, fueled by the success of Ozempic, Rybelsus, and Wegovy. Notably, the company hit a record free cash flow of $83.1 billion. Despite facing stiff competition, Novo Nordisk’s dominance in diabetes care and its knack for innovation position it favorably for sustained long-term growth.
United Therapeutics (UTHR): Charting a Path to Uncharted Horizons
Source: viewimage / Shutterstock.com
United Therapeutics (NASDAQ:UTHR) emerges as a specialty pharmaceutical player singularly focused on propelling rare lung diseases into the limelight. Renowned for its dominance in treating pulmonary arterial hypertension, the past year has been nothing short of transformative for the company.
With its commercial arm standing strong, United Therapeutics witnessed record revenue from Tyvaso in Q4 2023, marking a remarkable 41% year-over-year growth. Armed with a plethora of pipeline opportunities, including the promising bioengineered organ program, the company’s diversified portfolio sets it apart from the competition.
United Therapeutics’ laser focus on niche areas grants it the advantage of limited competition, allowing for premium pricing strategies. This translates into double-digit growth on both the top and bottom lines, as management confidently sets its sights on a $4 billion run rate by 2025. In a landscape teeming with opportunity, United Therapeutics emerges as a beacon of untapped potential in 2024.
Vertex Pharmaceuticals (VRTX): Pioneering a Path to Progress
Source: Pavel Kapysh / Shutterstock.com
Vertex Pharmaceuticals (NASDAQ:VRTX) takes the helm as a Boston-based biotechnology juggernaut, specializing in transforming the treatment landscape for Cystic Fibrosis (CF). For years, therapies for CF were limited, but Vertex has ushered in a new era of possibilities.
Revolutionizing the treatment of cystic fibrosis, Vertex’s flagship drugs – Trikafta and Kalydeco – have set the gold standard in CF care. This success has propelled the company to new heights, with accelerated revenue growth and EPS expansion in its wake. Nevertheless, the excitement on Wall Street is palpable, as Vertex’s pipeline beyond CF promises a world of opportunity in 2024.
Noteworthy among these prospects is the pending FDA approval for the VX-548 drug, currently in Phase 3 trials with plans for a new drug application submitted by mid-2024. While Vertex’s primary focus lies in a niche market, the chronic nature of CF ensures a steady and expanding patient base. Coupled with the remarkable efficacy of its drugs, Vertex wields considerable pricing power, translating into substantial revenue and free cash flow from operations. With a relentless commitment to research and development and a commanding stance in CF treatment, Vertex’s growth trajectory appears primed for continued ascent.
On the date of publication, Terel Miles did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
